Cargando…

The interactions of novel mononuclear platinum-based complexes with DNA

BACKGROUND: Cisplatin has been widely used for the treatment of cancer and its antitumour activity is attributed to its capacity to form DNA adducts, predominantly at guanine residues, which impede cellular processes such as DNA replication and transcription. However, there are associated toxicity a...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Ben W., Burgess, Mark W., Murray, Vincent, Aldrich-Wright, Janice R., Temple, Mark D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303901/
https://www.ncbi.nlm.nih.gov/pubmed/30577821
http://dx.doi.org/10.1186/s12885-018-5194-8
_version_ 1783382252746440704
author Johnson, Ben W.
Burgess, Mark W.
Murray, Vincent
Aldrich-Wright, Janice R.
Temple, Mark D.
author_facet Johnson, Ben W.
Burgess, Mark W.
Murray, Vincent
Aldrich-Wright, Janice R.
Temple, Mark D.
author_sort Johnson, Ben W.
collection PubMed
description BACKGROUND: Cisplatin has been widely used for the treatment of cancer and its antitumour activity is attributed to its capacity to form DNA adducts, predominantly at guanine residues, which impede cellular processes such as DNA replication and transcription. However, there are associated toxicity and drug resistance issues which plague its use. This has prompted the development and screening of a range of chemotherapeutic drug analogues towards improved efficacy. The biological properties of three novel platinum-based compounds consisting of varying cis-configured ligand groups, as well as a commercially supplied compound, were characterised in this study to determine their potential as anticancer agents. METHODS: The linear amplification reaction was employed, in conjunction with capillary electrophoresis, to quantify the sequence specificity of DNA adducts induced by these compounds using a DNA template containing telomeric repeat sequences. Additionally, the DNA interstrand cross-linking and unwinding efficiency of these compounds were assessed through the application of denaturing and native agarose gel electrophoresis techniques, respectively. Their cytotoxicity was determined in HeLa cells using a colorimetric cell viability assay. RESULTS: All three novel platinum-based compounds were found to induce DNA adduct formation at the tandem telomeric repeat sequences. The sequence specificity profile at these sites was characterised and these were distinct from that of cisplatin. Two of these compounds with the enantiomeric 1,2-diaminocyclopentane ligand (SS and RR-DACP) were found to induce a greater degree of DNA unwinding than cisplatin, but exhibited marginally lower DNA cross-linking efficiencies. Furthermore, the RR-isomer was more cytotoxic in HeLa cells than cisplatin. CONCLUSIONS: The biological characteristics of these compounds were assessed relative to cisplatin, and a variation in the sequence specificity and a greater capacity to induce DNA unwinding was observed. These compounds warrant further investigations towards developing more efficient chemotherapeutic drugs.
format Online
Article
Text
id pubmed-6303901
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63039012018-12-31 The interactions of novel mononuclear platinum-based complexes with DNA Johnson, Ben W. Burgess, Mark W. Murray, Vincent Aldrich-Wright, Janice R. Temple, Mark D. BMC Cancer Research Article BACKGROUND: Cisplatin has been widely used for the treatment of cancer and its antitumour activity is attributed to its capacity to form DNA adducts, predominantly at guanine residues, which impede cellular processes such as DNA replication and transcription. However, there are associated toxicity and drug resistance issues which plague its use. This has prompted the development and screening of a range of chemotherapeutic drug analogues towards improved efficacy. The biological properties of three novel platinum-based compounds consisting of varying cis-configured ligand groups, as well as a commercially supplied compound, were characterised in this study to determine their potential as anticancer agents. METHODS: The linear amplification reaction was employed, in conjunction with capillary electrophoresis, to quantify the sequence specificity of DNA adducts induced by these compounds using a DNA template containing telomeric repeat sequences. Additionally, the DNA interstrand cross-linking and unwinding efficiency of these compounds were assessed through the application of denaturing and native agarose gel electrophoresis techniques, respectively. Their cytotoxicity was determined in HeLa cells using a colorimetric cell viability assay. RESULTS: All three novel platinum-based compounds were found to induce DNA adduct formation at the tandem telomeric repeat sequences. The sequence specificity profile at these sites was characterised and these were distinct from that of cisplatin. Two of these compounds with the enantiomeric 1,2-diaminocyclopentane ligand (SS and RR-DACP) were found to induce a greater degree of DNA unwinding than cisplatin, but exhibited marginally lower DNA cross-linking efficiencies. Furthermore, the RR-isomer was more cytotoxic in HeLa cells than cisplatin. CONCLUSIONS: The biological characteristics of these compounds were assessed relative to cisplatin, and a variation in the sequence specificity and a greater capacity to induce DNA unwinding was observed. These compounds warrant further investigations towards developing more efficient chemotherapeutic drugs. BioMed Central 2018-12-22 /pmc/articles/PMC6303901/ /pubmed/30577821 http://dx.doi.org/10.1186/s12885-018-5194-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Johnson, Ben W.
Burgess, Mark W.
Murray, Vincent
Aldrich-Wright, Janice R.
Temple, Mark D.
The interactions of novel mononuclear platinum-based complexes with DNA
title The interactions of novel mononuclear platinum-based complexes with DNA
title_full The interactions of novel mononuclear platinum-based complexes with DNA
title_fullStr The interactions of novel mononuclear platinum-based complexes with DNA
title_full_unstemmed The interactions of novel mononuclear platinum-based complexes with DNA
title_short The interactions of novel mononuclear platinum-based complexes with DNA
title_sort interactions of novel mononuclear platinum-based complexes with dna
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303901/
https://www.ncbi.nlm.nih.gov/pubmed/30577821
http://dx.doi.org/10.1186/s12885-018-5194-8
work_keys_str_mv AT johnsonbenw theinteractionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT burgessmarkw theinteractionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT murrayvincent theinteractionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT aldrichwrightjanicer theinteractionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT templemarkd theinteractionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT johnsonbenw interactionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT burgessmarkw interactionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT murrayvincent interactionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT aldrichwrightjanicer interactionsofnovelmononuclearplatinumbasedcomplexeswithdna
AT templemarkd interactionsofnovelmononuclearplatinumbasedcomplexeswithdna